newsfilter
← Latest News
PR Newswire·

Kuehn Law Encourages Investors of Regenxbio, Inc. to Contact Law Firm

  • Kuehn Law, PLLC is investigating potential fiduciary duty breaches by officers & directors of Regenxbio, Inc. (NASDAQ: RGNX).
  • The firm alleges the company provided false or misleading information regarding the efficacy & safety of RGX-111, a gene therapy for Hurler Syndrome.
  • Allegations include unjustified positive assertions about future trial success based on Phase I/II biomarker & safety data.
  • Shareholders who purchased RGNX prior to February 9, 2022, are urged to contact attorney Sophia Anne Silayan for potential legal action.
  • Kuehn Law covers all case costs & does not charge investor clients.
  • Contact details for Kuehn Law include email, phone, & physical address in Southampton, NY.